Grants for Nonprofits - Consumer Protection

This competition invites individuals and teams worldwide to develop innovative, leak-resistant packaging solutions for large liquid detergent bottles that meet Amazon's distribution standards, with a focus on usability and manufacturing integration.

This funding opportunity supports U.S.-based organizations in conducting research to better understand and manage heart-related side effects of cancer treatments, with a focus on improving detection, monitoring, and data sharing.

This grant provides funding for individuals and organizations in Washington, DC, to create projects that celebrate and preserve the culture and heritage of local communities, culminating in a public event to showcase their work.

This program provides funding to California-based organizations and businesses to promote sustainable farming practices and improve access to healthy food in diverse communities.

The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.

The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited. The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.

Restricted to California nonprofit organizations that are described under Section 501(c)(3) of the Internal Revenue Code of 1986 (IRC) and exempt from tax under Section 501(a) of such code. The Internal Revenue Service (IRS) does not require certain organizations such as churches, mosques, and synagogues to apply for and receive recognition of exemption under Section 501(c)(3) of the IRC. Such organizations are automatically exempt if they meet the requirements of Section 501(c)(3).

This funding opportunity supports individuals and organizations in Washington, DC, to document and preserve the oral histories of local residents, focusing on community collaboration and culturally significant themes.

This funding opportunity supports a national initiative to educate and empower Medicare beneficiaries and their families against fraud and abuse, by providing resources and training to organizations dedicated to this mission across the U.S. and its territories.

This grant provides financial support to citrus growers in select California counties to implement sustainable farming practices that improve soil health, enhance climate resilience, and promote environmental stewardship, with a focus on assisting socially disadvantaged farmers, women, and veterans.

The FY2025 LGBTQIA+ Violence Prevention & Response Team (VPART) Grant, offered by the Executive Office of Mayor Muriel Bowser and the Mayor’s Office of Lesbian, Gay, Bisexual, Transgender, and Questioning Affairs (MOLGBTQA), aims to prevent crime and address violence against the LGBTQIA+ community in the District of Columbia. This grant directly aligns with MOLGBTQA's mission to convene community and government agencies to reduce violence and harm against members of the LGBTQIA+ community. The grant seeks to support qualified community-based organizations (CBOs) that can coordinate the VPART team, provide services to LGBTQIA+ crime victims, and empower other CBOs through training. The primary target beneficiaries for these funds are individuals who identify as Lesbian, Gay, Bisexual, Transgender, and Questioning, with a specific focus on those at a higher risk of being targeted by hate crimes and bias incidents. The overall impact goal is to address and mitigate violence within the LGBTQIA+ community and further reduce violence and harm through comprehensive support, education, and outreach. Expected outcomes include improved support for victims navigating legal and social service systems, increased access to culturally appropriate mental health services, enhanced community education on harm reduction, and strengthened capacity of CBOs to serve the LGBTQIA+ population. The grant prioritizes two main service areas: Violence Response Services and Victim Prevention Outreach. Violence Response Services include case management to assist victims through criminal, civil legal, and social service systems; legal services providing professional advice on criminal proceedings; and trauma-informed mental health services linking individuals to culturally appropriate and victim-centered care. Victim Prevention Outreach focuses on cultural humility training for organizations serving the LGBTQIA+ population, community education to reduce physical or emotional harm through workshops and campaigns, and harm reduction interventions providing resources and connections to addiction treatment. Organizations applying for this grant are encouraged to demonstrate their full capacity by applying to as many services and programs as possible within these funding areas. The MOLGBTQA's strategic approach, or theory of change, is rooted in the belief that by bringing together public safety, human services agencies, and community organizations, they can effectively prevent crime, support victims, and build community resilience against violence. This collaborative model, facilitated by the VPART meetings and supported by designated grantee organizations, is intended to lead to measurable results in reduced violence and improved well-being for the LGBTQIA+ community in Washington, DC.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

The purpose of this NOFO is: 1) To facilitate long-term improvements to the national food safety system by strengthening interagency collaboration, improving the states;apos; regulatory and surveillance protection programs for manufactured foods, conducting research, and promoting the Manufactured Food Regulatory Program Standards (MFRPS); and 2) The continued development, implementation, management, and support of a funding system for those state and territorial agencies that have primary responsibility for regulating Grade A milk or molluscan shellfish (or both). Such agencies may apply and be sub-awarded funds to facilitate training, equipment purchases, or provide for other priorities needed to implement the Grade "A" Milk Safety program and the National Shellfish Sanitation Program (NSSP) within their respective jurisdictions.

Description: The Illinois Grocery Initiative aims to establish new grocery stores in food deserts to increase access to fresh food in underserved areas. This grant, under the funding opportunity number FY24-2 and CSFA number 420-35-3295, anticipates awarding 8 grants with a total program funding of $14,000,000. Eligible projects must involve capital expenditures, as operational costs are not covered. Grants will range from $160,000 to $2,400,000, and applicants are required to meet cost-sharing requirements. The application window opens on 04/09/2024 and closes on 05/24/2024. Indirect costs are allowed but restricted to capital-only expenditures. There are mandatory and optional technical assistance sessions provided to assist applicants, with registration required through provided links.

This program provides financial support to small-scale, sustainable farms in metro Atlanta to improve their operations and enhance their contributions to the local food system.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established. This grant will support the continued advancement of FDA;apos;s initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

The "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required" grant aims to fund clinical trials that test the effectiveness and safety of new treatments for rare diseases, with the goal of increasing the number of approved treatments for these conditions.

The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

This grant provides financial support to organizations that participate in California Public Utilities Commission activities, helping to remove barriers to their involvement in policy decision-making processes.

This grant invites private sector companies and organizations to collaborate with USAID on projects that address economic growth, financial inclusion, and environmental sustainability, leveraging their resources and expertise to achieve shared development goals.